Guangzhou Baiyunshan Pharmaceutical Holdings 과거 수익 실적
과거 기준 확인 2/6
Guangzhou Baiyunshan Pharmaceutical Holdings은 연평균 7.1%의 비율로 수입이 증가해 온 반면, Healthcare 산업은 수입이 증가했으며, 연간 11.8%였습니다. 매출은 연평균 4.7%의 비율로 증가했습니다. Guangzhou Baiyunshan Pharmaceutical Holdings의 자기자본이익률은 9.5%이고 순이익률은 4.5%입니다.
주요 정보
7.1%
수익 성장률
7.1%
EPS 성장률
| Healthcare 산업 성장 | 11.3% |
| 매출 성장률 | 4.7% |
| 자기자본 수익률 | 9.5% |
| 순이익 | 4.5% |
| 최근 수익 업데이트 | 30 Sep 2024 |
최근 과거 실적 업데이트
Recent updates
Guangzhou Baiyunshan Pharmaceutical Holdings' (HKG:874) Shareholders Have More To Worry About Than Only Soft Earnings
Nov 01
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Recorded A 7.9% Miss On Revenue: Analysts Are Revisiting Their Models
Oct 29Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?
Oct 17Here's What's Concerning About Guangzhou Baiyunshan Pharmaceutical Holdings' (HKG:874) Returns On Capital
Sep 25Earnings Report: Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Missed Revenue Estimates By 8.1%
Sep 04A Look At The Fair Value Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874)
Jul 15Returns At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Appear To Be Weighed Down
Jun 26Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Is Increasing Its Dividend To CN¥0.8227
Jun 03The CEO Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Might See A Pay Rise On The Horizon
May 23Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?
May 13Do Guangzhou Baiyunshan Pharmaceutical Holdings' (HKG:874) Earnings Warrant Your Attention?
Mar 08Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Intrinsic Value Is Potentially 33% Above Its Share Price
Feb 23Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has More To Do To Multiply In Value Going Forward
Feb 10Does Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Have A Healthy Balance Sheet?
Jan 25Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Popularity With Investors Is Under Threat From Overpricing
Jan 09With EPS Growth And More, Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Makes An Interesting Case
Nov 28A Look At The Intrinsic Value Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874)
Nov 15We Think Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Can Manage Its Debt With Ease
Oct 19Returns On Capital At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Have Hit The Brakes
Oct 03Is Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Worth HK$21.9 Based On Its Intrinsic Value?
Aug 15Should You Be Adding Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) To Your Watchlist Today?
Aug 02Guangzhou Baiyunshan Pharmaceutical Holdings' (HKG:874) Returns Have Hit A Wall
Jul 02Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?
Jun 01Here's Why Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has Caught The Eye Of Investors
May 01The Returns At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Aren't Growing
Mar 28Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Could Easily Take On More Debt
Feb 23With EPS Growth And More, Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Makes An Interesting Case
Jan 23Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has Some Way To Go To Become A Multi-Bagger
Dec 24Estimating The Fair Value Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874)
Nov 24Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Using Too Much Debt?
Nov 11Does Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Have A Healthy Balance Sheet?
Aug 02Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Is Paying Out A Larger Dividend Than Last Year
May 30Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Intrinsic Value Is Potentially 83% Above Its Share Price
Apr 29Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Could Easily Take On More Debt
Apr 10We Think Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Can Manage Its Debt With Ease
Jan 09Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has A Rock Solid Balance Sheet
Oct 11Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?
Jul 12Why We Think Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) CEO Compensation Is Not Excessive At All
May 26How Does Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Stand Up To These Simple Dividend Safety Checks?
Apr 30Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Shares Could Be 21% Above Their Intrinsic Value Estimate
Apr 08These 4 Measures Indicate That Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Is Using Debt Reasonably Well
Mar 25Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Mar 02Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Shareholders Have Enjoyed A 24% Share Price Gain
Feb 11
Is Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) A Smart Pick For Income Investors?
Jan 26Could The Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Ownership Structure Tell Us Something Useful?
Jan 06Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has A Pretty Healthy Balance Sheet
Dec 23Here's Why We Don't Think Guangzhou Baiyunshan Pharmaceutical Holdings's (HKG:874) Statutory Earnings Reflect Its Underlying Earnings Potential
Dec 09Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?
Nov 26수익 및 비용 분석
수익 및 비용 분석
Guangzhou Baiyunshan Pharmaceutical Holdings 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.
수익 및 매출 내역
| 날짜 | 수익 | 수익 | G+A 비용 | R&D 비용 |
|---|---|---|---|---|
| 30 Sep 24 | 76,391 | 3,423 | 8,016 | 781 |
| 30 Jun 24 | 76,588 | 3,794 | 8,404 | 773 |
| 31 Mar 24 | 76,833 | 4,105 | 8,595 | 789 |
| 31 Dec 23 | 75,515 | 4,056 | 8,558 | 782 |
| 30 Sep 23 | 74,167 | 4,283 | 8,644 | 735 |
| 30 Jun 23 | 73,538 | 4,188 | 8,405 | 779 |
| 31 Mar 23 | 71,878 | 4,069 | 8,260 | 760 |
| 31 Dec 22 | 70,788 | 3,967 | 8,117 | 819 |
| 30 Sep 22 | 70,280 | 3,883 | 8,060 | 934 |
| 30 Jun 22 | 70,106 | 3,807 | 8,308 | 930 |
| 31 Mar 22 | 69,507 | 3,898 | 8,143 | 927 |
| 31 Dec 21 | 69,014 | 3,720 | 8,050 | 875 |
| 30 Sep 21 | 68,329 | 3,568 | 7,632 | 814 |
| 30 Jun 21 | 67,333 | 3,653 | 7,193 | 729 |
| 31 Mar 21 | 64,735 | 3,359 | 6,997 | 664 |
| 31 Dec 20 | 61,674 | 2,915 | 6,496 | 612 |
| 30 Sep 20 | 61,774 | 2,688 | 6,091 | 516 |
| 30 Jun 20 | 62,081 | 2,406 | 6,896 | 569 |
| 31 Mar 20 | 63,881 | 2,966 | 7,131 | 539 |
| 31 Dec 19 | 64,952 | 3,189 | 7,799 | 577 |
| 30 Sep 19 | 62,420 | 3,161 | 8,567 | 657 |
| 30 Jun 19 | 60,735 | 3,370 | 8,083 | 620 |
| 31 Mar 19 | 53,380 | 3,943 | 7,784 | 621 |
| 31 Dec 18 | 42,234 | 3,441 | 6,772 | 585 |
| 30 Sep 18 | 34,863 | 4,015 | 6,271 | 521 |
| 30 Jun 18 | 24,679 | 3,523 | 5,601 | 482 |
| 31 Mar 18 | 22,575 | 2,482 | 5,408 | 510 |
| 01 Jan 18 | 20,954 | 2,062 | 5,502 | 373 |
| 30 Sep 17 | 20,459 | 1,937 | 4,619 | 244 |
| 30 Jun 17 | 20,294 | 1,834 | 4,742 | 134 |
| 31 Mar 17 | 20,273 | 1,583 | 5,257 | 0 |
| 31 Dec 16 | 20,036 | 1,508 | 5,232 | 0 |
| 30 Sep 16 | 19,598 | 1,397 | 5,934 | 0 |
| 30 Jun 16 | 19,502 | 1,357 | 5,907 | 0 |
| 31 Mar 16 | 19,442 | 1,345 | 5,839 | 0 |
| 31 Dec 15 | 19,125 | 1,300 | 5,509 | 0 |
| 30 Sep 15 | 19,244 | 1,300 | 5,281 | 0 |
| 30 Jun 15 | 19,270 | 1,295 | 5,291 | 0 |
| 31 Mar 15 | 18,876 | 1,241 | 5,190 | 0 |
| 31 Dec 14 | 18,818 | 1,194 | 5,189 | 0 |
| 30 Sep 14 | 19,049 | 1,106 | 5,135 | 0 |
| 30 Jun 14 | 18,563 | 1,067 | 4,877 | 0 |
| 31 Mar 14 | 18,130 | 1,036 | 4,718 | 0 |
| 31 Dec 13 | 17,608 | 980 | 4,641 | 0 |
양질의 수익: 874 은 높은 수익을 보유하고 있습니다.
이익 마진 증가: 874 의 현재 순이익 이익률 (4.5%) 작년보다 낮습니다 (5.8%).
잉여현금흐름 대 수익 분석
과거 수익 성장 분석
수익추이: 874 의 수입은 지난 5년 동안 매년 7.1% 씩 증가했습니다.
성장 가속화: 874 은(는) 지난 1년 동안 마이너스 수익 성장을 기록했기 때문에 5년 평균과 비교할 수 없습니다.
수익 대 산업: 874 은 지난 1년 동안 마이너스 수익 성장( -20.1% )을 기록하여 Healthcare 업계 평균( -16.9% ).
자기자본 수익률
높은 ROE: 874 의 자본 수익률( 9.5% )은 낮음으로 간주됩니다.